Myomo Inc
AMEX:MYO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth $-5.85 (804% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.8 | $0.83 |
0%
|
| Industry Average | 12.9 | $-5.85 |
-804%
|
| Country Average | 14.4 | $-6.52 |
-884%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
M
|
Myomo Inc
AMEX:MYO
|
32m USD | -1.8 | -2.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 44.4 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 14 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 19.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 12.8 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 17.7 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 23.5 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 10.7 | 18.9 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 30.6 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 9.7 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 15.3 | 21.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Myomo Inc
Glance View
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
